PhRMA

Congress should make sure savings on medicines go to patients, not PBMs. https://lnkd.in/eg_x6As7

Since first reported in the early 1980s, HIV/AIDS has gone from a death sentence to a manageable condition with a normal life expectancy. While we're proud of the progress made in the fight against HIV/AIDS, there's still more work to be done. Learn more as we commemorate #WorldAIDSDay: https://lnkd.in/eHKADeg8

State auditors in Minnesota released today a 340B report that paints a stark picture. Eligible hospitals and clinics in the state made at least $630 million in 340B profits in 2023. Hospitals are marking up the price of medicines with little charity care rates to show and the program’s benefit to patients remains unclear. Even worse, the report states that this figure is likely as little as half of the actual total 340B profits for eligible Minnesota providers. What’s worse, middlemen siphoned more than $120 million from the program, representing $16 out of every $100 of 340B dollars. Large hospitals, big pharmacies, PBMs and others rake in huge profits while patients, taxpayers and employers foot the bill. While this level of clarity is sorely needed in 340B, the important question of how Minnesota patients – and patients in states across the country – benefit from this program remains. https://lnkd.in/eGgdjwiJ

American Enterprise Institute Nonresident Fellow Kirsten Axelsen discusses the significance of cross-sector collaboration in developing innovative cancer medicines and how recent policies endanger these valuable relationships.

Antibiotic-resistant infections are directly associated with over 1.2 million deaths per year. Without intervention, the threat of antimicrobial resistance (AMR) will only continue to grow. Vaccines are our greatest tool against evolving public health threats like AMR. If rolled out for all 23 evaluated pathogens in recent World Health Organization research, vaccines could reduce the number of antibiotics needed by 22% every year, and save one-third of the hospital costs associated with AMR. #WAAW #AMR https://lnkd.in/g37jBnY9

As an industry, we’ve made incredible progress in transforming diabetes care over the past century. This #AmericanDiabetesMonth, we recognize the important role innovation plays in improving the health of patients living with the disease and understand the critical need for a policy environment that prioritizes affordable access to life-saving diabetes treatments. Hear more from PhRMA’s Senior Director of Public Affairs & Strategic Initiatives, Drew Voytal, MPA-HCA, who has lived with type 1 diabetes for most of his life:

The biopharmaceutical industry is projected to spend over $100 billion a year to bring new medicines to patients, but 4 in 10 patients still face issues accessing the treatments they need. On November 21, PhRMA’s Chief Operating Officer, Lori Reilly will participate in a WTOP News webinar about the barriers to medicines imposed by middlemen and the legislative action needed to protect patient access. Register to watch here: https://lnkd.in/epr9uKV6

Hear Samaritan Health Services President Andrew von Eschenbach M.D discuss the importance of regulatory policies that allow medicine research and development to thrive.

Today, 90% of prescriptions for medicines are filled with generics. CEO Stephen Ubl describes how the market supports ongoing innovation and lowers costs for patients.

A recent study from Health Affairs examines the impact of the Inflation Reduction Act’s prescription drug price setting on post-approval R&D, a critical driver in the fight against cancer. Did you know? For nearly 9 out of 10 (89%) approved cancer medicines, additional clinical trials were initiated after the initial approval to explore new uses. In fact, more than half of all cancer medicine indications were approved after that first FDA approval. This post-approval research is essential for unlocking new treatment options for patients.    Health Affairs’ findings add to the growing body of evidence detailing the IRA’s unintended consequences. We know what’s wrong with the law. Now lawmakers need to fix it. https://lnkd.in/gAq-P65A